IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC)

被引：69

作者：

Motzer, Robert J.

Powles, Thomas

Atkins, Michael B.

Escudier, Bernard

McDermott, David F.

Suarez, Cristina

Bracarda, Sergio

Stadler, Walter Michael

Donskov, Frede

Lee, Jae-Lyun

Hawkins, Robert E.

Ravaud, Alain

Alekseev, Boris Y.

Staehler, Michael D.

Uemura, Motohide

Donaldson, Francis

Li, Shi

Huseni, Mahrukh A.

Schiff, Christina

Rini, Brian I.

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY USA

[2] Barts Hlth NHS Trust St Bartholomews Hosp, London, England

[3] Georgetown Univ Lombardi Comprehens Canc Ctr, Washington, DC USA

[4] Inst Gustave Roussy, Villejuif, France

[5] Beth Israel Deaconess Med Ctr, Boston, MA USA

[6] Univ Autonoma Barcelona, Vall Hebron Univ Hosp, Vall Hebron Inst Oncol, Barcelona, Spain

[7] Osped San Donato, Arezzo, Italy

[8] Univ Chicago, Chicago, IL USA

[9] Aarhus Univ Hosp, Aarhus, Denmark

[10] Univ Ulsan Coll Med Asan Med Ctr, Seoul, South Korea

[11] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England

[12] Bordeaux Univ Hosp, Bordeaux, France

[13] Moscow Res Oncol Inst, Fed State Inst, Moscow, Russia

[14] Univ Hosp Munich Grosshadern, Ludwig Maximilian Univ, Munich, Germany

[15] Osaka Univ Grad Sch Med, Osaka, Japan

[16] F Hoffmann La Roche Ltd, Basel, Switzerland

[17] Genentech Inc, South San Francisco, CA USA

[18] Cleveland Clin Taussig Canc Inst, Cleveland, OH USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 06期

关键词：

D O I：

10.1200/JCO.2018.36.6_suppl.578

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

578

引用

页数：2